Molecular Detection of


Journal

Journal of clinical microbiology
ISSN: 1098-660X
Titre abrégé: J Clin Microbiol
Pays: United States
ID NLM: 7505564

Informations de publication

Date de publication:
23 08 2023
Historique:
medline: 25 8 2023
pubmed: 24 7 2023
entrez: 24 7 2023
Statut: ppublish

Résumé

Molecular detection of Orthohantavirus puumalaense (PUUV) RNA during the course of the disease has been studied in blood of patients in Sweden and Slovenia. The use of urine has been poorly investigated. The aims of this work were to study PUUV RNA detection in plasma from a cohort of patients in France where a different PUUV lineage circulates and to assess the use of urine instead of plasma. Matched plasma and urine samples were collected daily from hospitalized patients presenting with fever, pain, and thrombocytopenia within the last 8 days and testing positive for IgM and IgG against PUUV in serum collected at inclusion and/or approximately 1 month after release. RNA was extracted from samples, and PUUV RNA was detected using real-time reverse transcription-PCR for plasma and urine samples. Sixty-seven patients presented a serologically confirmed acute hantavirus infection. At inclusion, PUUV RNA was detected in plasma from 55 of 62 patients (88.7%) sampled within the first week after disease onset, whereas it was detected in 15 of 60 (25.0%) of matched urine samples. It was then detected from 33 (71.7%) and 2 (4.4%) of 46 patients discharged from the hospital during the second week after disease onset, in plasma and urine, respectively. When PUUV RNA was detected in urine it was also detected in plasma, and not vice versa. Detection of PUUV RNA in plasma from hospitalized patients in France is similar to that observed in Sweden and Slovenia. Urine is not an appropriate sample for this detection.

Identifiants

pubmed: 37486218
doi: 10.1128/jcm.00372-23
pmc: PMC10446862
doi:

Substances chimiques

RNA, Viral 0
Antibodies, Viral 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0037223

Déclaration de conflit d'intérêts

The authors declare no conflict of interest.

Références

J Clin Microbiol. 2007 Aug;45(8):2491-7
pubmed: 17537944
J Clin Microbiol. 1997 May;35(5):1090-6
pubmed: 9114386
J Clin Microbiol. 2016 May;54(5):1335-9
pubmed: 26962084
Clin Microbiol Infect. 2014 Mar;20(3):235-41
pubmed: 23742660
BMC Infect Dis. 2018 Dec 29;18(1):707
pubmed: 30594124
J Virol. 2009 May;83(10):5046-55
pubmed: 19279096
Microorganisms. 2021 Jun 16;9(6):
pubmed: 34208593
PLoS Negl Trop Dis. 2021 Sep 28;15(9):e0009707
pubmed: 34582439
Clin Microbiol Infect. 2013 Aug;19(8):E358-66
pubmed: 23573903
Am J Trop Med Hyg. 2021 Aug 09;105(5):1285-1289
pubmed: 34370707
J Clin Virol. 2001 Apr;21(1):63-74
pubmed: 11255099
Microbes Infect. 2004 Feb;6(2):238-45
pubmed: 15049335
Microbes Infect. 2001 Nov;3(13):1129-44
pubmed: 11709294
Clin Chem. 2007 Nov;53(11):1899-905
pubmed: 17717126
Clin Microbiol Infect. 2019 Apr;21S:e6-e16
pubmed: 24750436
J Infect Dis. 1992 May;165(5):934-7
pubmed: 1349033
J Infect Dis. 2006 Nov 15;194(10):1403-9
pubmed: 17054070
Emerg Infect Dis. 2021 Feb;27(2):658-660
pubmed: 33496646
Expert Rev Anti Infect Ther. 2013 May;11(5):479-87
pubmed: 23627854
J Med Virol. 2010 Oct;82(10):1773-81
pubmed: 20827776
J Clin Microbiol. 1995 Feb;33(2):277-82
pubmed: 7714178
J Infect Dis. 2018 Oct 5;218(10):1622-1630
pubmed: 29917112
J Clin Microbiol. 2012 Jun;50(6):2047-52
pubmed: 22442323
J Infect Dis. 2001 Feb 15;183(4):532-8
pubmed: 11170977
Emerg Infect Dis. 2019 Jan;25(1):140-143
pubmed: 30561320
Antiviral Res. 2013 Dec;100(3):589-604
pubmed: 24126075

Auteurs

Jean-Marc Reynes (JM)

Institut Pasteur, Université Paris Cité, Unité Environnement et Risques Infectieux, Centre National de Référence Hantavirus, Paris, France.

Laura Schaeffer (L)

Institut Pasteur, Université Paris Cité, Unité Epidémiologie des Maladies Emergentes, Paris, France.

Pavlos Papadopoulos (P)

Institut Pasteur, Université Paris Cité, Unité Environnement et Risques Infectieux, Centre National de Référence Hantavirus, Paris, France.

Mohand Ait-Ahmed (M)

Institut Pasteur, Université Paris Cité, Centre de Recherche Translationnelle, Paris, France.

Dieyenaba Siby-Diakite (D)

Institut Pasteur, Université Paris Cité, Unité Environnement et Risques Infectieux, Centre National de Référence Hantavirus, Paris, France.

Maryline Ripaux-Lefèvre (M)

Institut Pasteur, Université Paris Cité, Unité Environnement et Risques Infectieux, Centre National de Référence Hantavirus, Paris, France.

Tan-Phuc Buivan (TP)

Institut Pasteur, Université Paris Cité, Centre de Recherche Translationnelle, Paris, France.

Sylvie Lechat (S)

Centre Hospitalier Intercommunal nord Ardennes, Laboratoire de Biologie Médicale, Charleville- Mézières, France.

Muriel Vray (M)

Institut Pasteur, Université Paris Cité, Unité Epidémiologie des Maladies Emergentes, Paris, France.

Jean-Marc Galempoix (JM)

Centre Hospitalier Intercommunal nord Ardennes, Service de Médecine Interne et Maladies Infectieuses, Charleville- Mézières, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH